Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
- 26 October 2023
- journal article
- research article
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 77 (10) , 671-813
Abstract
Die aktuelle Fassung der Leitlinie Lungenkarzinom trägt der Dynamik der Informationen in diesem Fachbereich Rechnung. Insbesondere gelten folgenden Empfehlungen: Die Vorstellung aller neu diagnostizierten Patienten im interdisziplinären pneumoonkologischen Tumorboard ist verpflichtend, das CT-Screening für asymptomatische Risikopersonen (nach Zulassung durch die Behörden), Vorgehen beim inzidentellen Lungenrundherd (außerhalb von Screeningprogrammen), molekulare Testung aller NSCLC unabhängig vom Subtyp, in frühen Stadien auf EGFR-Mutationen und in der Rezidivsituation, adjuvante TKI-Therapie bei Vorliegen einer EGFR-Mutation, adjuvante Konsolidierung mit Checkpointinhibitor bei PD-L1 ≥ 50%, Erhebung des PD-L1-Status, nach Radiochemotherapie bei PD-L1-pos. Tumoren Konsolidierung mit Checkpointinhibitor, adjuvante Konsolidierung mit Checkpointinhibitor bei PD-L1 ≥ 50% im Stadium IIIA, Erweiterung des therapeutischen Spektrums bei PD-L1 ≥ 50%, unabhängig von PD-L1Status, neue zielgerichtete Therapieoptionen sowie die Einführung der Immunchemotherapie in der SCLC Erstlinie. Um eine zeitnahe Umsetzung künftiger Neuerungen zu gewährleisten, wurde die Umstellung auf eine „living guideline“ für das Lungenkarzinom befürwortet. The current S3 Lung Cancer Guidelines are edited with fundamental changes to the previous edition based on the dynamic influx of information to this field: The recommendations include de novo a mandatory case presentation for all patients with lung cancer in a multidisciplinary tumor board before initiation of treatment, furthermore CT-Screening for asymptomatic patients at risk (after federal approval), recommendations for incidental lung nodule management , molecular testing of all NSCLC independent of subtypes, EGFR-mutations in resectable early stage lung cancer in relapsed or recurrent disease, adjuvant TKI-therapy in the presence of common EGFR-mutations, adjuvant consolidation treatment with checkpoint inhibitors in resected lung cancer with PD-L1 ≥ 50%, obligatory evaluation of PD-L1-status, consolidation treatment with checkpoint inhibition after radiochemotherapy in patients with PD-L1-pos. tumor, adjuvant consolidation treatment with checkpoint inhibition in patients withPD-L1 ≥ 50% stage IIIA and treatment options in PD-L1 ≥ 50% tumors independent of PD-L1status and targeted therapy and treatment option immune chemotherapy in first line SCLC patients. Based on the current dynamic status of information in this field and the turnaround time required to implement new options, a transformation to a „living guideline“ was proposed. Article published online: 26 October 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 124 references indexed in Scilit:
- Radiation Therapy Oncology Group Protocol 02-29: A Phase II Trial of Neoadjuvant Therapy With Concurrent Chemotherapy and Full-Dose Radiation Therapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-small Cell Carcinoma of the LungInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Morphine Versus Midazolam as Upfront Therapy to Control Dyspnea Perception in Cancer Patients While Its Underlying Cause Is Sought or TreatedJournal of Pain and Symptom Management, 2010
- Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced CancerJAMA, 2009
- Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysisCancer Causes & Control, 2009
- Relief of Incident Dyspnea in Palliative Cancer Patients: A Pilot, Randomized, Controlled Trial Comparing Nebulized Hydromorphone, Systemic Hydromorphone, and Nebulized SalineJournal of Pain and Symptom Management, 2008
- Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced CancerJournal of Pain and Symptom Management, 2006
- Nebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary StudyJournal of Pain and Symptom Management, 2005
- Kommunikation in der OnkologieDer Onkologe, 2004
- Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trialSupportive Care in Cancer, 2004
- Im Spannungsfeld zwischen Informed Consent und konfliktvermeidender Fehlinformation: Patientenaufklärung unter ökonomischen Zwängen. Ergebnisse einer empirischen StudieEthik in der Medizin, 1999